FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2101265454> ?p ?o ?g. }

• W2101265454 endingPage "248" @default.
• W2101265454 startingPage "243" @default.
• W2101265454 abstract "The duration of anticoagulation after venous thromboembolic events (VTE) is based on the balance between the risk of recurrent VTE and bleeding. The purpose of this study was to estimate the frequency and case-fatality rate of major bleeding and recurrent VTE during secondary prevention of VTE.MEDLINE, EMBASE, and Cochrane Central Register of Controlled Trials databases were searched through September 2014. Two reviewers independently screened citations to identify trials that enrolled patients for secondary prevention of VTE with direct oral anticoagulants (DOACs), vitamin K antagonists (VKAs), aspirin or placebo. Two reviewers independently extracted data onto standardized forms.Twelve RCTs that enrolled 10,542 patients were included. The rate of major bleeding was 1.6 per 100 patient-years (95% CI, 1.2-2.1), and 0.58 per 100 patient-years (95% CI, 0.24-1.1) on VKAs and DOACs, respectively, with an incidence rate ratio of 0.35 (95% CI, 0.17-0.68, p=0.0023). The case-fatality rates for DOACs and VKAs were not significantly different at 0% (95% CI, 0.0-15.4) and 6.8% (95% CI, 1.4-18.6), respectively. The rate of recurrent VTE was not different between DOACs and VKA, IRR 0.88 (95% CI, 0.15-4.8, p=0.88). Case-fatality rates for recurrent VTE for DOAC and VKAs were 10.8% (95% CI, 4.4-20.9) and 5.6% (95% CI, 1.2-15.4), respectively. Only DOACs showed a significant reduction in the composite outcome of fatal recurrent VTE and fatal bleeding when compared to placebo, IRR 0.40 (95% CI, 0.14-1.0, p=0.03).Case-fatality rates for major bleeding and recurrent VTE for DOACs appear to be similar to those for VKA and the composite of fatal events is lower for DOACs than placebo. Overall, given the favorable safety profile and comparable efficacy of DOAC therapy, the threshold to continue anticoagulation with DOACs after unprovoked VTE should be low if the baseline risk of anticoagulation-related bleeding is not high." @default.
• W2101265454 created "2016-06-24" @default.
• W2101265454 creator A5012144838 @default.
• W2101265454 creator A5062783662 @default.
• W2101265454 creator A5066454760 @default.
• W2101265454 creator A5073652700 @default.
• W2101265454 creator A5077442829 @default.
• W2101265454 date "2015-02-01" @default.
• W2101265454 modified "2023-10-17" @default.
• W2101265454 title "Case-fatality of recurrent venous thromboembolism and major bleeding associated with aspirin, warfarin, and direct oral anticoagulants for secondary prevention" @default.
• W2101265454 cites W1573523596 @default.
• W2101265454 cites W1975990989 @default.
• W2101265454 cites W1978280229 @default.
• W2101265454 cites W1983782921 @default.
• W2101265454 cites W2012519169 @default.
• W2101265454 cites W2022713742 @default.
• W2101265454 cites W2043306284 @default.
• W2101265454 cites W2059305858 @default.
• W2101265454 cites W2067741035 @default.
• W2101265454 cites W2074708727 @default.
• W2101265454 cites W2076621544 @default.
• W2101265454 cites W2098923148 @default.
• W2101265454 cites W2101863341 @default.
• W2101265454 cites W2102778065 @default.
• W2101265454 cites W2107328434 @default.
• W2101265454 cites W2112378432 @default.
• W2101265454 cites W2112757583 @default.
• W2101265454 cites W2115787552 @default.
• W2101265454 cites W2118092611 @default.
• W2101265454 cites W2126930838 @default.
• W2101265454 cites W2130199362 @default.
• W2101265454 cites W2130288184 @default.
• W2101265454 cites W2134833483 @default.
• W2101265454 cites W2135918458 @default.
• W2101265454 cites W2139785591 @default.
• W2101265454 cites W2149388786 @default.
• W2101265454 cites W2156320702 @default.
• W2101265454 cites W2160625453 @default.
• W2101265454 cites W2162531249 @default.
• W2101265454 cites W2164443169 @default.
• W2101265454 cites W2166402206 @default.
• W2101265454 cites W2169472792 @default.
• W2101265454 cites W2327974959 @default.
• W2101265454 cites W2331935930 @default.
• W2101265454 cites W2568332688 @default.
• W2101265454 cites W2989714602 @default.
• W2101265454 doi "https://doi.org/10.1016/j.thromres.2014.10.033" @default.
• W2101265454 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25488466" @default.
• W2101265454 hasPublicationYear "2015" @default.
• W2101265454 type Work @default.
• W2101265454 sameAs 2101265454 @default.
• W2101265454 citedByCount "36" @default.
• W2101265454 countsByYear W21012654542013 @default.
• W2101265454 countsByYear W21012654542016 @default.
• W2101265454 countsByYear W21012654542017 @default.
• W2101265454 countsByYear W21012654542018 @default.
• W2101265454 countsByYear W21012654542019 @default.
• W2101265454 countsByYear W21012654542020 @default.
• W2101265454 countsByYear W21012654542021 @default.
• W2101265454 countsByYear W21012654542022 @default.
• W2101265454 countsByYear W21012654542023 @default.
• W2101265454 crossrefType "journal-article" @default.
• W2101265454 hasAuthorship W2101265454A5012144838 @default.
• W2101265454 hasAuthorship W2101265454A5062783662 @default.
• W2101265454 hasAuthorship W2101265454A5066454760 @default.
• W2101265454 hasAuthorship W2101265454A5073652700 @default.
• W2101265454 hasAuthorship W2101265454A5077442829 @default.
• W2101265454 hasConcept C107130276 @default.
• W2101265454 hasConcept C120665830 @default.
• W2101265454 hasConcept C121332964 @default.
• W2101265454 hasConcept C126322002 @default.
• W2101265454 hasConcept C142724271 @default.
• W2101265454 hasConcept C167704817 @default.
• W2101265454 hasConcept C187316915 @default.
• W2101265454 hasConcept C204787440 @default.
• W2101265454 hasConcept C27081682 @default.
• W2101265454 hasConcept C2776301958 @default.
• W2101265454 hasConcept C2777628954 @default.
• W2101265454 hasConcept C2779161974 @default.
• W2101265454 hasConcept C2780868729 @default.
• W2101265454 hasConcept C2991741193 @default.
• W2101265454 hasConcept C44249647 @default.
• W2101265454 hasConcept C61511704 @default.
• W2101265454 hasConcept C71924100 @default.
• W2101265454 hasConceptScore W2101265454C107130276 @default.
• W2101265454 hasConceptScore W2101265454C120665830 @default.
• W2101265454 hasConceptScore W2101265454C121332964 @default.
• W2101265454 hasConceptScore W2101265454C126322002 @default.
• W2101265454 hasConceptScore W2101265454C142724271 @default.
• W2101265454 hasConceptScore W2101265454C167704817 @default.
• W2101265454 hasConceptScore W2101265454C187316915 @default.
• W2101265454 hasConceptScore W2101265454C204787440 @default.
• W2101265454 hasConceptScore W2101265454C27081682 @default.
• W2101265454 hasConceptScore W2101265454C2776301958 @default.
• W2101265454 hasConceptScore W2101265454C2777628954 @default.
• W2101265454 hasConceptScore W2101265454C2779161974 @default.
• W2101265454 hasConceptScore W2101265454C2780868729 @default.
• W2101265454 hasConceptScore W2101265454C2991741193 @default.

• next